Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.40 |
| ▸ | GCG | P01275 | 13/20 | 0.35 |
| ▸ | GCGR | P47871 | 3/20 | 0.35 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.33 |
| ▸ | SMO | Q99835 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22701706 | 0.75 | EGLN1 (0.50) | EGLN1 | |
| SCHEMBL25489183 | 0.71 | CYP2A6 (0.36) | — | |
| SCHEMBL3513409 | 0.71 | CYP2A6 (0.36) | — | |
| SCHEMBL30144069 | 0.71 | CYP2A6 (0.36) | — | |
| SCHEMBL19501370 | 0.70 | EGLN1 (0.51) | EGLN1PANK3 | |
| SCHEMBL26422895 | 0.68 | HDAC4 (0.46) | GCGGCGRHDAC4 | |
| SCHEMBL22605742 | 0.67 | EGLN1 (0.47) | EGLN1 | |
| SCHEMBL25875342 | 0.67 | MAPT (0.36) | EGLN1GCGGCGRHDAC4 | |
| SCHEMBL11899574 | 0.66 | GCG (0.45) | EGLN1GCGGCGR | |
| SCHEMBL21744564 | 0.65 | EGLN1 (0.45) | EGLN1SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975084-B2 | KDM5 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200048258-A1 | KDM5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048258-A1 | KDM5 INHIBITORS | KDM5A, KDM5B, KDM5C | EGLN1 397/4885GCG 4723/4885GCGR 3896/4885 |
| US-10975084-B2 | KDM5 inhibitors | KDM5A, KDM5B, KDM5C | EGLN1 397/4885GCG 4723/4885GCGR 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.